The TRIPLEX study: use of patient-derived tumor organoids as an innovative tool for precision medicine in triple-negative breast cancer.

Jordane Divoux,Romane Florent,Margaux Jacobs,Justine Lequesne,Jean-Michel Grellard, Chankannira San, Sara Grossi, Katia Kerdja,Bénédicte Clarisse, Gwenaelle Boudier,François Cherifi,Mélanie Briand,Enora Dolivet, Alisson Johnson, Brice Dubois,Valentin Harter,Joëlle Lacroix,Charlotte Raboutet, Brigitte Marie,Nathalie Rousseau,Cécile Blanc-Fournier,Dominique Vaur,Martin Figeac,Laurent Poulain,Louis-Bastien Weiswald,George Emile

BMC cancer（2023）

引用 0|浏览15

暂无评分

摘要

The clinical trial (version 1.2) has been validated by local research ethic committee on December 30 2021 and registered at ClinicalTrials.gov with the identifier NCT05404321 on June 3 2022, version 1.2.

查看译文

关键词

Triple negative breast cancer,Patient-derived tumor organoids,Predictive functional assays,Chemo-immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要